425: Boston Scientific to Acquire Penumbra for $14.5B

Boston Scientific Corporation announced a definitive agreement to acquire Penumbra, Inc. for approximately $14.5 billion in a cash and stock transaction, expanding its cardiovascular and neurovascular portfolios.

Summary

• Penumbra, Inc. (PEN) will be acquired by Boston Scientific Corporation (BSX) for an enterprise value of approximately $14.5 billion.
• Penumbra shareholders will receive $374.00 per share, with an election to receive either cash or 3.8721 shares of Boston Scientific common stock.
• The total consideration will be prorated to be approximately 73.26% cash and 26.74% Boston Scientific stock.
• The acquisition is expected to be dilutive to Boston Scientific's adjusted EPS by $0.06-$0.08 in the first full year post-close, becoming neutral to slightly accretive in the second year and more accretive thereafter.
• Penumbra reported preliminary Q4 2025 revenue of $383.0 million to $384.8 million, representing 21.4% to 22.0% growth year-over-year.
• Full year 2025 preliminary revenue was $1,401.3 million to $1,403.1 million, a growth of 17.3% to 17.5% over 2024.
• Preliminary Q4 2025 operating margin was 14.8% to 15.7%, and full year 2025 operating margin was 13.3% to 13.6%.
• The transaction is expected to close in 2026, subject to Penumbra stockholder and regulatory approvals.

Sentiment

Score: 8

Explanation: The filing announces a significant acquisition at a substantial premium for Penumbra shareholders, coupled with strong preliminary financial results for Penumbra. While there's initial dilution for Boston Scientific, the strategic rationale and long-term growth potential are positive. The preliminary nature of financials and integration risks temper the score slightly.

Positives

• Penumbra reported strong preliminary Q4 2025 revenue growth of 21.4% to 22.0% (23.2% to 23.8% excluding China).
• Full year 2025 preliminary revenue growth was also robust at 17.3% to 17.5% (24.7% to 24.9% excluding China).
• The acquisition provides Penumbra shareholders with a significant premium at $374 per share, reflecting an enterprise value of approximately $14.5 billion.
• The merger is not subject to a financing condition, indicating Boston Scientific has secured funding.
• Penumbra's CEO, Adam Elsesser, will join Boston Scientific's board of directors, suggesting continuity and integration of leadership.
• Penumbra is described as the "world's leading thrombectomy company" with innovative technologies for challenging medical conditions.

Negatives

• The acquisition is expected to be dilutive to Boston Scientific's adjusted earnings per share by $0.06-$0.08 in the first full year post-acquisition.
• GAAP earnings per share for Boston Scientific are also expected to be dilutive in the first full year due to amortization and acquisition-related charges.
• Preliminary financial results are unaudited and subject to change, which introduces a degree of uncertainty.
• The merger agreement includes a $525,000,000 termination fee payable by Penumbra under certain circumstances, which could be a significant cost if the deal falls through due to Penumbra's actions.

Risks

• Failure to consummate the proposed transaction on anticipated terms and timing, including obtaining stockholder and regulatory approvals.
• Failure to realize the anticipated benefits of the proposed transaction, including delays in completing the transaction or integrating the businesses.
• Potential litigation relating to the proposed transaction against Penumbra or its directors.
• Disruptions from the proposed transaction harming Penumbra's business, including current plans and operations.
• Ability of Penumbra to retain and hire key personnel during the pendency of the transaction.
• Potential adverse reactions or changes to business relationships resulting from the announcement, pendency, or completion of the proposed transaction.
• Uncertainty as to the long-term value of Boston Scientific's common stock, particularly for Penumbra shareholders electing stock consideration.
• Legislative, regulatory, and economic developments affecting Penumbra's business.
• General economic and market developments and conditions.
• The evolving legal, regulatory, and tax regimes under which Penumbra operates.
• Potential business uncertainty, including changes to existing business relationships, during the pendency of the proposed transaction that could affect Penumbra's financial performance.
• Restrictions during the pendency of the proposed transaction that may impact Penumbra's ability to pursue certain business opportunities or strategic transactions.
• Unpredictability and severity of catastrophic events, including acts of terrorism, war, or hostilities.
• Failure to receive the approval of Penumbra's stockholders.

Future Outlook

The transaction is expected to be completed in 2026. Boston Scientific anticipates the acquisition to be dilutive to its adjusted EPS by $0.06-$0.08 in the first full year post-close, becoming neutral to slightly accretive in the second year and more accretive thereafter. Penumbra expects to continue advancing its technologies with a multi-year research and development plan and ongoing clinical programs.

Management Comments

• "I'm thrilled to combine the talents and shared values of our teams – including welcoming Penumbra's chairman and chief executive officer, Adam Elsesser, to our board of directors upon close. The addition of Penumbra can expand access for these novel technologies to more patients and customers around the world, further enhancing our revenue and margins over time with proven offerings that have a history of growth and innovation." Mike Mahoney, Chairman and CEO, Boston Scientific.
• "Our decades-long development of therapies for challenging medical conditions has focused on deep innovation for complex diseases so that we can offer physicians novel solutions to transform patient care. I am grateful for the amazing people who have contributed to this work and look forward to uniting our efforts and shared values as we come together with Boston Scientific." Adam Elsesser, Chairman and CEO, Penumbra.

Industry Context

This acquisition positions Boston Scientific to significantly expand its cardiovascular portfolio and gain a scaled entry into the fast-growing mechanical thrombectomy and neurovascular segments. Given that cardiovascular diseases are the leading cause of death globally, Penumbra's comprehensive portfolio of differentiated devices for conditions like ischemic stroke, pulmonary embolism, and acute limb ischemia directly addresses a critical and expanding market need. The integration of Penumbra's innovative technologies, particularly its computer-assisted vacuum thrombectomy (CAVT) systems, enhances Boston Scientific's offerings and competitive standing in these strategic adjacencies.

Comparison to Industry Standards

• Penumbra's preliminary Q4 2025 revenue growth of 21.4% to 22.0% and full year 2025 growth of 17.3% to 17.5% (or 23.2%-23.8% and 24.7%-24.9% excluding China) indicates strong performance, likely outpacing many competitors in the broader medical device sector, especially within the specialized thrombectomy and neurovascular markets.
• The acquisition price of $374 per share, reflecting an enterprise value of approximately $14.5 billion, suggests a substantial premium, which is common for leading innovative companies in high-growth medical technology segments. This valuation implies Boston Scientific sees significant strategic value and future growth potential in Penumbra's portfolio and market position, similar to other high-profile M&A deals in the med-tech space where strategic fit and market leadership command higher multiples.
• Boston Scientific's expectation of initial EPS dilution followed by accretion is a typical financial profile for strategic acquisitions of high-growth companies, where the immediate integration costs and purchase price accounting impact are offset by long-term revenue growth and synergy realization.

Management Changes

Corporate Governance

Legal Proceedings

• The filing mentions potential litigation relating to the proposed transaction that could be instituted against Penumbra or its directors.
• The Company agrees to give Parent reasonable opportunity to participate in the defense of any Transaction Litigation and consult on settlement.

Related Party Transactions

• As of the date of this Agreement, there are no transactions, contracts, arrangements, commitments or understandings between the Company or the Company Subsidiaries, on the one hand, and any of the Company’s Affiliates, on the other hand, that would be required to be disclosed by the Company under Item 404 of Regulation S-K under the Securities Act.

Stakeholder Impact

• Shareholders (Penumbra): Will receive $374 per share, with an election for cash or Boston Scientific stock, representing a significant premium.
• Shareholders (Boston Scientific): Will experience initial EPS dilution but expect long-term accretion and expanded market presence.
• Employees (Penumbra): Continuing employees will receive no less favorable base salary/wage, comparable incentive opportunities, and substantially comparable aggregate employee benefits for one year post-merger. Service credit for eligibility, vesting, and benefit accrual will be recognized.
• Customers: Expanded access to novel technologies and a broader portfolio from the combined entity.
• Management (Penumbra): CEO Adam Elsesser will join Boston Scientific's board, indicating a degree of continuity and integration at the leadership level.

Next Steps

• Penumbra stockholders to vote on the adoption of the Merger Agreement.
• Boston Scientific to file a registration statement on Form S-4 with the SEC, including a proxy statement/prospectus.
• Form S-4 needs to be declared effective by the SEC.
• Boston Scientific shares to be issued in the merger need NYSE listing approval.
• HSR Act waiting period and other required antitrust approvals must expire or be terminated/obtained.
• The Company Stockholders Meeting will be called, convened, and held to obtain approval.
• Penumbra's securities will be delisted from the NYSE and deregistered under the Exchange Act after the Effective Time.
• Boston Scientific will finance the cash portion of the transaction with cash on hand and new debt.
• The transaction is expected to be completed in 2026.

Key Dates

Recommendation

The acquisition of Penumbra by Boston Scientific at a significant premium of $374 per share, reflecting an enterprise value of $14.5 billion, is a highly positive event for Penumbra shareholders. The preliminary financial results for Penumbra show robust revenue growth (21.4%-22.0% in Q4 2025 and 17.3%-17.5% for FY 2025), indicating a strong underlying business performance. For Boston Scientific, while there is an expected initial EPS dilution, the strategic rationale of gaining scaled entry into fast-growing mechanical thrombectomy and neurovascular markets, coupled with Penumbra's innovative portfolio and market leadership, suggests significant long-term value creation. The absence of a financing condition further de-risks the transaction. This strategic move is expected to enhance Boston Scientific's revenue and margins over time, making it an attractive long-term investment.

Keywords

Penumbra, Boston Scientific, Merger, Acquisition, Thrombectomy, Neurovascular, Cardiovascular, Medical Devices, SEC Filing, Financial Results, Stock Consideration, Cash Consideration, Healthcare, M&A